Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.

Orphanet J Rare Dis · 2024 · PMC11583740 · PMID 39574155

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Pharmacokinetic analyses in the nDNA cohort also showed a trend among subjects with higher elamipretide exposure (measured in plasma) and improved 6MWT.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.